These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21570913)

  • 21. Positron emission tomography in CNS drug discovery and drug monitoring.
    Piel M; Vernaleken I; Rösch F
    J Med Chem; 2014 Nov; 57(22):9232-58. PubMed ID: 25144329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.
    Langer O
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S143-56. PubMed ID: 27385172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative Rodent Brain Receptor Imaging.
    Herfert K; Mannheim JG; Kuebler L; Marciano S; Amend M; Parl C; Napieczynska H; Maier FM; Vega SC; Pichler BJ
    Mol Imaging Biol; 2020 Apr; 22(2):223-244. PubMed ID: 31168682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of emission tomography in pharmacokinetic and pharmacodynamic studies in clinical psychopharmacology.
    Malizia AL
    J Psychopharmacol; 2006 Jul; 20(4 Suppl):100-7. PubMed ID: 16785278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing a cassette microdosing approach to enhance the throughput of PET imaging agent screening.
    Xiao H; Sun M; Zhao R; Hong H; Zhang A; Zhang S; Liu F; Zhang Y; Liu Y; Zhu L; Kung HF; Qiao J
    J Pharm Biomed Anal; 2018 May; 154():48-56. PubMed ID: 29533858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography and drug discovery: contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization.
    Klimas MT
    Mol Imaging Biol; 2002 Oct; 4(5):311-37. PubMed ID: 14537107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection.
    Baker S; Chin CL; Basso AM; Fox GB; Marek GJ; Day M
    J Pharmacol Exp Ther; 2012 Apr; 341(1):263-73. PubMed ID: 22267203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody positron emission tomography imaging in anticancer drug development.
    Lamberts LE; Williams SP; Terwisscha van Scheltinga AG; Lub-de Hooge MN; Schröder CP; Gietema JA; Brouwers AH; de Vries EG
    J Clin Oncol; 2015 May; 33(13):1491-504. PubMed ID: 25779566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of neuroimaging in drug development.
    Medhi B; Misra S; Avti PK; Kumar P; Kumar H; Singh B
    Rev Neurosci; 2014; 25(5):663-73. PubMed ID: 24960151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.
    Grueneisen J; Nagarajah J; Buchbender C; Hoffmann O; Schaarschmidt BM; Poeppel T; Forsting M; Quick HH; Umutlu L; Kinner S
    Invest Radiol; 2015 Aug; 50(8):505-13. PubMed ID: 26115367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety biomarkers in preclinical development: translational potential.
    Sasseville VG; Mansfield KG; Brees DJ
    Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards molecular imaging of multiple sclerosis.
    Owen DR; Piccini P; Matthews PM
    Mult Scler; 2011 Mar; 17(3):262-72. PubMed ID: 21212087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2.
    Leurquin-Sterk G; Celen S; Van Laere K; Koole M; Bormans G; Langlois X; Van Hecken A; Te Riele P; Alcázar J; Verbruggen A; de Hoon J; Andrés JI; Schmidt ME
    J Nucl Med; 2017 Jan; 58(1):110-116. PubMed ID: 27469358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vivo imaging for biodistribution and metabolism evaluations of new chemical entities].
    Corot C; Idée JM; Raynaud JS; Salazar JF; Catoen S
    Ann Pharm Fr; 2012 Jan; 70(1):26-34. PubMed ID: 22341006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of biomarkers in the discovery of novel anti-schizophrenia drugs.
    Mikkelsen JD; Thomsen MS; Hansen HH; Lichota J
    Drug Discov Today; 2010 Feb; 15(3-4):137-41. PubMed ID: 20036755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
    Brand C; Longo VA; Groaning M; Weber WA; Reiner T
    Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical evaluation of CNS drugs with PET].
    Takano A
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):61-5. PubMed ID: 19562943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Target engagement in lead generation.
    Durham TB; Blanco MJ
    Bioorg Med Chem Lett; 2015 Mar; 25(5):998-1008. PubMed ID: 25630223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrating ADNI results into Alzheimer's disease drug development programs.
    Cummings JL
    Neurobiol Aging; 2010 Aug; 31(8):1481-92. PubMed ID: 20447734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioligand development for molecular imaging of the central nervous system with positron emission tomography.
    Honer M; Gobbi L; Martarello L; Comley RA
    Drug Discov Today; 2014 Dec; 19(12):1936-44. PubMed ID: 25173703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.